Saram ConsultingGxP & AI Consulting for Life Sciences. Custom AI integrations, Part 11 compliance validation, and equity-based engineering partnerships for biotech.Explore Services at saram.io →
← Back to Home

United Therapeutics

NASDAQ: UTHR ↗$494.63 USD~$15B MCAP
#Pulmonary Hypertension#Rare Diseases#Organ Transplant

United Therapeutics is a biotechnology company focused on developing therapies for pulmonary arterial hypertension and other rare diseases.

Company Info

Sector:Biopharmaceutical
Headquarters:Silver Spring, Maryland, United States
Founded:1996
Website:www.unither.com/

Upcoming Milestones & Key Dates

2026-Q4
Business

Thymic cell therapy integration

Clinical Development Pipeline

Tyvaso

Target: Prostacyclin
Pulmonary arterial hypertension
Preclinical
Phase 1
Phase 2
Phase 3
Approved

Orenitram

Target: Prostacyclin
Pulmonary arterial hypertension
Preclinical
Phase 1
Phase 2
Phase 3
Approved

Tymalor (oral treprostinil)

Target: Prostacyclin
Pulmonary hypertension associated with ILD
Preclinical
Phase 1
Phase 2
Phase 3
Approved

Recent News

Leadership Team

Martine Rothblatt

Chairperson and Chief Executive Officer

Michael Benkowitz

President and Chief Operating Officer

James Huang

Chief Financial Officer

Careers & Job Openings

See all open roles

Apply Now →